US Nuclear Joins The Brain-Machine Interface Revolution
Los Angeles, CA. February 10, 2020 – US Nuclear Corp. (OTC: UCLE) recently signed a stock purchase agreement with start-up Grapheton Inc. to acquire a 40% stake in the company.
Similar to Elon Musk’s ‘Neuralink’, Grapheton is developing and manufacturing an advanced new generation of wearable and implantable brain-machine interface devices. Grapheton’s long-term goal is dedicated specifically to treating injuries and diseases such as spinal injuries, pain reduction, Parkinson’s Disease, epilepsy, stroke, and possibly Alzheimer’s. Grapheton already has several pivotal and patented advantages in the field, including:
- Grapheton’s electrodes utilize a new carbon-based material that doesn’t corrode and can last as long as 40 years or more compared to less than five years from other providers, which is extremely important considering the invasive surgery required for installation or maintenance of the probes.
- A self-charging supercapacitor uses the brain’s own salty liquid environment as the power source, meaning that unlike other providers, no battery maintenance is required to reinstall a new battery while also ensuring that aging batteries will not leak any chemicals into the brain. Again, a huge advantage for reducing the surgery and maintenance required.
- Two-way electrical and chemical communication with brain neurons, meaning that Grapheton’s probes can not only send electrical signals, but also listen, record, and respond to the body’s electrical and chemical signals simultaneously.